<DOC>
	<DOCNO>NCT01977456</DOCNO>
	<brief_summary>The primary goal trial determine individual acute ischemic stroke treat full dose IV recombinant tissue plasminogen activator ( rt-PA ) plus IV eptifibatide start within 3 hour symptom onset likely well outcome individual treat standard IV rt-PA alone .</brief_summary>
	<brief_title>Study Combination Therapy Rt-PA Eptifibatide Treat Acute Ischemic Stroke ( CLEAR-FDR )</brief_title>
	<detailed_description>The Combined Approach Lysis Utilizing Eptifibatide rt-PA Acute Ischemic Stroke-Full Dose Regimen ( CLEAR-FDR Stroke Trial ) Phase II trial part Specialized Program Translational Research Acute Stroke ( SPOTRIAS ) . The overall goal SPOTRIAS enhance delivery acute stroke patient care train acute stroke translational researcher . Stroke often occur blood flow brain stop block blood clot . When blood clot block blood supply brain , part brain may get enough blood oxygen survive . As result , permanent brain damage occur , affect person 's ability walk , talk , function independently . In order reduce risk permanent damage , important restore blood flow brain quickly possible . rt-PA , use alone , already approve Food Drug Administration ( FDA ) treatment patient stroke caused blockage artery brain give within 3 hour onset stroke symptom . Eptifibatide also already FDA-approved treatment blood clot cause heart attack . The investigational aspect study use eptifibatide stroke victim combination rt-PA . The CLEAR Stroke Trial demonstrate combination low dose rt-PA plus eptifibatide safely give acute ischemic stroke patient within 3 hour symptom onset . The CLEAR-ER Stroke Trial demonstrate combination medium dose rt-PA plus eptifibatide safely give acute ischemic stroke patient within 3 hour symptom onset . The CLEAR-FDR Stroke Trial design provide data concern risk combine eptifibatide full dose intravenous rt-PA 30 acute ischemic stroke patient within 3 hour symptom onset .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Brain Infarction</mesh_term>
	<mesh_term>Eptifibatide</mesh_term>
	<criteria>Patients must serious measurable neurological deficit NIH Stroke Scale due focal brain ischemia . An NIH Stroke Scale score &gt; 5 time rtPA begin . Age : 18 85 year ( i.e . candidate must 18th birthday , 86th birthday ) . Intravenous rtPA therapy must initiate within 3 hour onset stroke symptom . History stroke past 3 month . Previous intracranial hemorrhage , neoplasm , subarachnoid hemorrhage , arterial venous malformation . Clinical presentation suggest subarachnoid hemorrhage , even initial CT scan normal . Hypertension time treatment ; systolic BP &gt; 185 diastolic &gt; 110 mmHg aggressive measure low blood pressure limit need . Presumed septic embolus . Presumed pericarditis include pericarditis acute myocardial infarction . Recent ( within 30 day ) surgery biopsy parenchymal organ . Recent ( within 30 day ) trauma , internal injury ulcerative wound . Recent ( within 90 day ) severe head trauma head trauma loss consciousness . Any active recent ( within 30 day ) serious systemic hemorrhage . Known hereditary acquire hemorrhagic diathesis , coagulation factor deficiency ; oral anticoagulant therapy International Normalized Ratio ( INR ) &gt; 1.7 . Baseline lab value : positive urine pregnancy test , glucose &lt; 50 &gt; 400 mg/dl , platelet &lt; 100,000 /mm3 , Hct &lt; 25 % , creatinine &gt; 4 mg/dl . Ongoing renal dialysis , regardless creatinine . Subjects receive Low Molecular Weight heparin ( Dalteparin , Enoxaparin , Tinzaparin ) deep vein thrombosis ( DVT ) prophylaxis full dose within previous 24 hour . Subjects receive heparin direct thrombin inhibitor ( bivalirudin , argatroban , lepirudin ) within 48 hour screen must normal partial prothrombin time ( PTT ) . Subjects received Factor Xa inhibitor ( fondaparinux ) direct thrombin inhibitor ( dabigatran ) within last 4 day . Arterial puncture noncompressible site lumbar puncture previous 7 day . Seizure onset stroke . Preexisting neurological psychiatric disease would confound neurological functional evaluation . Other serious , advanced , terminal illness condition investigator feel would pose significant hazard patient rtPA eptifibatide therapy initiate . Patients whose peripheral venous access poor unable two standard peripheral intravenous line start . Current participation another research drug treatment protocol . Patient start another experimental agent 90 day . Informed consent obtain . Any known history amyloid angiopathy . High density lesion consistent hemorrhage degree . Significant mass effect midline shift . Large ( 1/3 middle cerebral artery ) region clear hypodensity baseline CT scan . Sulcal effacement and/or loss greywhite differentiation alone contraindication treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>acute ischemic stroke</keyword>
	<keyword>stroke</keyword>
	<keyword>rt-PA , thrombolytic</keyword>
	<keyword>t-PA</keyword>
	<keyword>recombinant tissue plasminogen activator</keyword>
	<keyword>Activase</keyword>
	<keyword>eptifibatide</keyword>
	<keyword>Integrilin</keyword>
	<keyword>fibrinolytic agent</keyword>
	<keyword>clot dissolve</keyword>
	<keyword>blood clot</keyword>
</DOC>